Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2929–2952 of 10,535 matching trials from the live ClinicalTrials.gov search.

Filters: Active, not recruiting Clear all

Conditions: Normal Pressure Hydrocephalus
Interventions: CereVasc eShunt System, VP Shunt; Device
Lead sponsor: CereVasc Inc; Industry
Eligibility: 60 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 29
States / cities: Los Angeles, California • New Haven, Connecticut • Jacksonville, Florida + 21 more

Conditions: Advanced Solid Tumor
Interventions: Denikitug, Zimberelimab; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 10
States / cities: La Jolla, California • Palo Alto, California • New Haven, Connecticut + 6 more

Conditions: Colorectal Cancer
Interventions: Colonoscopy, Fecal immunochemical test (FIT); Procedure
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years to 75 Years
Enrollment: 50,126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2028
U.S. locations: 45
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 42 more

Conditions: Lung Cancer
Interventions: Blood Sample Collection; Other
Lead sponsor: Delfi Diagnostics Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 11,935 participants
Timeline: 2022 – 2026
U.S. locations: 66
States / cities: Cullman, Alabama • Culver City, California • Mission Hills, California + 55 more

Conditions: Obesity, Disorder of Lipid Storage and Metabolism, Lipid Metabolism Disorders, Metabolic Disorder
Interventions: Exercise; Behavioral
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 18 Years to 40 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Breast Neoplasms
Interventions: PD0332991, Anastrozole, Goserelin, Surgery (standard of care), Tumor biopsy; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 4
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Rochester, Minnesota + 1 more

Conditions: Rhabdomyosarcoma
Interventions: Vinorelbine, Mocetinostat; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 13 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Social Determinants of Health (SDOH)
Interventions: Survey using a questionnaire.; Other
Lead sponsor: BayCare Health System; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Prostate Cancer, High-risk Biochemical Recurrence, High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, Non-metastatic Castration-sensitive Prostate Cancer
Interventions: Xaluritamig; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 8
States / cities: Minneapolis, Minnesota • New York, New York • Chapel Hill, North Carolina + 5 more

Conditions: Acute Respiratory Distress Syndrome, Lung Diseases
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: CHF - Congestive Heart Failure, COPD, Pneumonia
Interventions: Transitional care model (TCM), Usual care; Behavioral
Lead sponsor: Mathematica Policy Research, Inc.; Other
Eligibility: 65 Years and older
Enrollment: 962 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Crohn Disease
Interventions: Xanthohumol, Placebo; Drug · Other
Lead sponsor: National University of Natural Medicine; Other
Eligibility: 21 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Tachycardia, Ventricular, Arrhythmia, Ventricular
Interventions: mCRM Therapy System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 18
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Jonesboro, Arkansas + 14 more

Conditions: Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
Interventions: TEDD-R, TEDDI-R, Ibrutinib, Cytarabine, Isavuconazole, Methotrexate; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Pain
Interventions: Verum VGAIT (Video-Guided Acupuncture Imagery Treatment), Sham VGAIT (Video-Guided Acupuncture Imagery Treatment); Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Brain Ischemia
Interventions: MRI, CT; Diagnostic Test
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 120 Years
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Newly Diagnosed Cancer Patients
Interventions: Hospital Counseling + Nicotine Replacement Therapy. questionaires, Hospital Counseling + Nicotine Replacement + Presurgical Scheduled Reduced Smoking, questionaires; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Duchenne Muscular Dystrophy
Interventions: Viltolarsen; Drug
Lead sponsor: NS Pharma, Inc.; Industry
Eligibility: Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 4
States / cities: Sacramento, California • Chicago, Illinois • Durham, North Carolina + 1 more

Conditions: Acute Myeloid Leukemia (AML)
Interventions: Azacitidine, Venetoclax, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 24
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 17 more

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma, Stage II Melanoma, Uveal Melanoma, Mucosal Melanoma, Unresectable Clear Cell Renal Cell Carcinoma
Interventions: Dietary Intervention, Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-Muscle Invasive Bladder Cancer (NMIBC)
Interventions: Bacillus Calmette-Guérin (BCG), Gemcitabine; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 8
States / cities: Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Non-small Cell Lung Cancer
Interventions: Osimertinib, Selumetinib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 4
States / cities: Boston, Massachusetts • Durham, North Carolina

Conditions: Cigarette Smoker, Tobacco Use Disorder
Interventions: Behavioral Intervention, Laboratory Biomarker Analysis, Nicotine Patch, Questionnaire Administration, Smoking Cessation Intervention; Behavioral · Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cardiogenic Shock
Interventions: Istaroxime, Placebo; Drug
Lead sponsor: Windtree Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts • Portland, Oregon

Search by objective public record fields.

Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM)

CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in Lung

Identification of Novel Skeletal Muscle-derived Factors That Promote Lipid Oxidation (Columbus)

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma

Effects of Social Determinants of Health on IV Iron Treatments

Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer

Molecular Epidemiology of Acute Respiratory Distress Syndrome (ARDS)

Transitional Care Model Evaluation 2020

A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease

Effectiveness of the EMPOWER™ Modular Pacing System and EMBLEM™ Subcutaneous ICD to Communicate Antitachycardia Pacing

Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)

Brain Mechanisms of Video-Guided Acupuncture Imagery Treatment on Chronic Low Back Pain

A Feasibility Study for Randomization of Code Stroke Imaging Strategies

Smoking Cessation Intervention for Cancer Patients

Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)

A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy

Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Behavioral Activation Therapy and Nicotine Replacement Therapy in Increasing Smoking Cessation

A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C